804, 322 - 11 AVENUE SW, CALGARY, A0
News, Articles of Incorporation, Bylaws
To Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Launches Randomized Colorectal Cancer Study
To Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Announces Results of Special Meeting of Shareholders
Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
FY 2025
Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities Issued in Business-Combination Transactions
Registration Statement for Securities Issued in Business-Combination Transactions
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Post-Effective Amendment to a Registration Statement for Securities of Certain Canadian Issuers
S-8 POS